Current Yield with Participation Funds (CYwP Funds) announced today that Current Yield with Participation Fund II (CYwP Fund II) has invested in Cellaria, a scientific innovator that is revolutionizing cancer research, patient testing and treatment development. Founded in 2013, the company’s goal is to revolutionize the investigation of the underlying mechanisms of disease, response to treatment and accelerate the search for more personalized therapies.
Cellaria’s core competency is in the production of highly validated, physiologically relevant cell models for disease and drug discovery research. The company’s products are comprised of cell models and media which are sold directly and through key distributor relationships.
Today, Cellaria’s capabilities also include defining and monitoring a collection of clinically relevant characteristics for each clinical disease category. Current customers include a variety of academic research facilities and biopharmaceutical companies.